Industry Bulletins | July 7, 2021
Cerevel Therapeutics Reports Positive Topline Results From Phase 1b Clinical Trial Of New Schizophrenia Medication
Cerevel Therapeutics Holdings Inc. reported positive results from its Phase 1b clinical trial of CVL-231, a novel muscarinic M4-selective positive allosteric modulator, in adults with schizophrenia. The medication was tested at two doses (30 mg once-daily and 20 mg twice-daily) for six weeks and compared to a placebo. Both doses demonstrated clinically meaningful antipsychotic activity.
The CVL-231 30 mg once-daily dose resulted in a statistically significant and clinically meaningful mean reduction from baseline of 19.5 points in the Positive and Negative Syndrome Scale total score and a mean reduction of 12.7 points . . .